Novo Nordisk Shares Slip 0.4% as Oral GLP-1 Scripts Fall First Week

NVO•2026-07-08

Novo Nordisk shares declined 0.4% after industry prescription data showed weekly U.S. scripts for its oral semaglutide GLP-1 pill dipped for the first time since launch. The slowdown in script growth could pressure revenue forecasts for the second half of 2026.

1. Prescription Data Indicates First Weekly GLP-1 Script Decline

Industry prescription tracking data revealed that weekly U.S. scripts for Novo Nordisk’s oral semaglutide GLP-1 treatment fell in the most recent week, marking the first downturn since its market debut. Analysts highlight that this deviation from steady growth could signal shifting demand dynamics for the company’s flagship diabetes and weight-management therapy.

2. Share Price Response and Revenue Implications

Following the report, Novo Nordisk’s stock dipped roughly 0.4% as investors weighed the implications of slower script momentum. The unexpected moderation has prompted some firms to revise down second-half 2026 revenue projections, raising concerns about the sustainability of GLP-1 uptake amid increasing competition.